┬╗ Portfolio News

10.02.17

NOXXON Pharma announces experienced Industry Cancer Clinician Dr. Jarl Ulf Jungnelius to serve as NOXXON CMO

Read more...

04.01.17

NOXXON Pharma licenses and assigns preclinical Spiegelmer programs to Aptarion

Read more...

15.12.16

NOXXON Pharma signs clinical immuno-oncology Collaboration Agreement with MSD to study NOX-A12 combined with Keytruda® (Pembrolizumab) in panacreatic and colorectal Cancer

Read more...

05.12.16

NOXXON Pharma Announces New Preclinical Data Showing Synergy of Lead Compound NOX-A12 With Natural Killer (NK) Cell Mediated Therapies 

Read more...

30.11.16

NOXXON Pharma N.V.: First Berlin startet Coverage mit Kaufempfehlung, 

Kursziel EUR 40,00 

Read more...